MedTrace Logo

AZD 2066 Single Dose Formulation and Food Effect Study in Healthy Volunteers

NCT00690404 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2010-12-10

No results posted yet for this study

Summary

A open label two way crossover formulation and food effect study in healthy volunteers to assess the pharmacokinetics of a single dose of AZD2066 new oral solid formulation and an oral solution

Conditions

  • Healthy

Interventions

DRUG

AZD2066

single oral dose

Sponsors & Collaborators

Principal Investigators

  • Eleanor Lisbon, MD, MPH · Quintiles, Inc. Overland Park, Kansas, USA

  • Heather Wray, MB, ChB, FFPM · AstraZeneca Charnwood England

  • Ivan Eggens, MD · AstraZeneca , Södertälje, Sweden

Study Design

Allocation
RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2008-06-30
Completion
2008-06-30

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00690404 on ClinicalTrials.gov